|[January 28, 2014]
Arrowhead to Report Fiscal 2014 First Quarter Financial Results
PASADENA, Calif. --(Business Wire)--
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that it
will report its financial results for the fiscal 2014 first quarter
ended December 31, 2013, on Tuesday, February 4, 2014, at 4:30 p.m.
Eastern time. To participate in the conference call, please dial
877-300-8521 (toll free from the US), 855-669-9657 (toll free from
Canada), or 412-317-6026 (for international callers). Investors may also
access a live audio webcast of this conference call on the Company's
website at http://www.arrowheadresearch.com/presentations.
A replay of the webcast will be aailable approximately one hour after
the conclusion of the call and will remain available for 90 days. An
audio replay will also be available approximately two hours after the
conclusion of the call and will be available for 30 days. The audio
replay can be accessed by dialing 877-870-5176 (toll free from the US
and Canada), or 858-384-5517 (for international callers) and entering
Event ID 10040388.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
drug delivery technologies to develop targeted drugs based on the RNA
interference mechanism that efficiently silence disease-causing genes.
Arrowhead technologies also enable partners to create peptide-drug
conjugates that specifically home to cell types of interest while
sparing off-target tissues. Arrowhead's pipeline includes clinical
programs in chronic hepatitis B virus and partner-based programs in
obesity and oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter (News - Alert) @ArrowRes.
To be added to the Company's email list to receive news directly, please
send an email to firstname.lastname@example.org.
[ InfoTech Spotlight's Homepage ]